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MUC4 immunohistochemistry 
is useful in distinguishing 
epithelioid mesothelioma from 
adenocarcinoma and squamous cell 
carcinoma of the lung
Amany Sayed Mawas1,2, Vishwa Jeet Amatya  1, Kei Kushitani1, Yuichiro Kai1,3,  
Yoshihiro Miyata3, Morihito Okada3 & Yukio Takeshima1
The differential diagnosis of epithelioid mesothelioma from lung adenocarcinoma and squamous 
cell carcinoma requires the positive and negative immunohistochemical markers of mesothelioma. 
The IMIG guideline has suggested the use of Calretinin, D2–40, WT1, and CK5/6 as mesothelial 
markers, TTF-1, Napsin-A, Claudin 4, CEA as lung adenocarcinoma markers p40, p63, CK5/6, 
MOC-31 as squamous cell markers. However, use of other immunohistochemical markers is still 
necessary. We evaluated 65 epithelioid mesotheliomas, 60 adenocarcinomas, and 57 squamous 
cell carcinomas of the lung for MUC4 expression by immunohistochemistry and compared with the 
previously known immunohistochemical markers. MUC4 expression was not found in any of 65 cases 
of epithelioid mesothelioma. In contrast, MUC4 expression was observed in 50/60(83.3%) cases of 
lung adenocarcinoma and 50/56(89.3%) cases of lung squamous cell carcinoma. The negative MUC4 
expression showed 100% sensitivity, 86.2% specificity and accuracy rate of 91.2% to differentiate 
epithelioid mesothelioma from lung carcinoma. The sensitivity, specificity, and accuracy of MUC4 are 
comparable to that of previously known markers of lung adenocarcinoma and squamous cell carcinoma, 
namely CEA, Claudin 4 and better than that of MOC-31. In conclusion, MUC4 immunohistochemistry is 
useful for differentiation of epithelioid mesothelioma from lung carcinoma, either adenocarcinoma or 
squamous cell carcinoma.
Malignant mesothelioma is a highly aggressive malignant neoplasm with unfavorable prognosis. The mortality 
from mesothelioma is increasing in Japan, and other developing countries1. Some of the non-mesotheliomatous 
peripheral lung cancer, adenocarcinoma or squamous cell carcinoma, may present as the pleurotropic growth 
resembling that of mesothelioma2. As the prognosis and treatment protocols of epithelioid mesothelioma are 
different from that of the lung cancer, accurate diagnosis of mesothelioma is crucial.
Mesothelioma is classified into three major histological subtypes: epithelioid, biphasic, and sarcomatoid mes-
othelioma. Epithelioid mesothelioma shows numerous histological growth pattern3. Due to this resemblance 
of clinical growth pattern and histology of epithelioid mesothelioma with lung cancers, immunohistochemical 
markers are essential for accurate diagnosis of epithelioid mesothelioma.
Although IMIG (International Mesothelioma Interest Group) recommended Calretinin, D2–40 (podoplanin), 
WT1 as mesothelioma markers, CEA, TTF-1, Napsin-A, as lung adenocarcinoma markers, and p63, p40, MOC-
31 as for lung squamous carcinoma markers4, the additional immunohistochemical markers will surely benefit 
in some unusual cases.
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We recently proposed the addition of two immunohistochemical markers, Intelectin-1 and DAB2, as the pos-
itive immunohistochemical markers of epithelioid mesothelioma5. In this study, we also found the down regula-
tion of many other genes including MUC4 in epithelioid mesothelioma as mentioned in its supplementary data.
Therefore, we evaluated the diagnostic applicability of MUC4 immunohistochemistry for differentiation of 
epithelioid mesothelioma to lung adenocarcinoma and squamous cell carcinoma.
Materials and Methods
Patients and Histologic Samples. Pathological specimens (formalin-fixed paraffin-embedded tissue 
blocks) of 65 epithelioid mesotheliomas and 60 lung adenocarcinoma and 57 squamous cell carcinoma were 
obtained from the tissue archives of the Department of Pathology, Hiroshima University. We also reviewed the 
patient’s clinical details and chest computed tomography findings for confirmation of the tumor localization. The 
mean age of lung adenocarcinoma patients was 69 with range from 43 to 84 (male 38, female 22), that of lung 
squamous cell carcinoma was 69 with range from 39 to 86 (male 49, female 7), and that of epithelioid mesotheli-
oma 69 with range from 33–92 (male 61, female 4).
All histological sections were examined and reclassified by three pathologists (VJA, KK, and YT) according 
to recent WHO classification6. Pathologic diagnosis was confirmed by histologic findings and the immunohis-
tochemical marker panel recommended by 2012 International Mesothelioma Interest Group (IMIG) guideline4. 
The collection of tissue specimens for this study was carried out in accordance with the “Ethics Guidelines for 
Human Genome/Gene Research” enacted by the Japanese Government. Ethical approval was obtained from the 
institutional ethics review committee (Hiroshima University E-974). All experimental procedures were in accord-
ance with the with ethical guidelines. Samples used were linked-anonymised archival specimens, and individual 
consent was not required for this research.
Immunohistochemical Procedures and Evaluation of MUC4 Expression. Immunohistoc
hemistry was performed using 3 μm tissue sections prepared from the best representative formalin-fixed 
paraffin-embedded blocks of epithelioid mesothelioma, lung adenocarcinoma, and squamous cell carcinoma 
cases. Immunohistochemical staining was performed using the Ventana Benchmark GX automated immuno-
histochemical station (Roche Diagnostics, Tokyo, Japan). The antigen retrieval methods and antibodies used in 
this study are summarized in Table 1. Incubation with the secondary antibody and detection was performed with 
Ventana ultraView Universal DAB Detection Kit (Roche Diagnostics). Immunoreactivity was evaluated as either 
negative or positive. Nuclear staining of calretinin, WT1, p40, p63, and TTF-1, cytoplasmic staining of MUC4 
and Napsin-A, CK5/6, CEA, membranous staining of podoplanin (clone: D2–40), Epithelial Related Antigen 
(clone: MOC-31) and claudin 4 were considered as ‘positive’.
Positive Immunoreactivity was semi quantitatively scored as 0 for none to trace, 1+ for up to 10%, 2+ for 
10–50%, and 3+ for >50% tumor cells showing positive expression.
Statistical analyses were performed using the Fisher’s exact test for calculation of p-value of positivity of indi-
vidual markers, Mann Whitney U test for calculation Z-score and the p-value of immunohistochemical score of 
individual markers. Sensitivity, specificity, and accuracy rate are calculated using a 2 × 2 contingency table model.
Results
Immunohistochemical Result. The percentages and immunohistochemical scores of MUC4 expression in 
epithelioid mesothelioma, lung adenocarcinoma, and squamous cell carcinoma and other immunohistochemical 
markers are shown in Table 2.
MUC4 expression. MUC4 expression was not present in any of 65 epithelioid mesotheliomas (0%, 
Fig. 1B,D). MUC4 expression was present in the cytoplasm of the tumor cell of lung adenocarcinoma and squa-
mous cell carcinoma. It was also evident in the normal bronchial epithelium, considered as an internal positive 
Antibody to Clone Source Dilution Antigen Retrieval
MUC4 8G7 Santa Cruz Biotech 1:25 60 min, CC1
Calretinin SP65 Ventana-Roche prediluted 30 min, CC1
Podoplanin D2–40 Nichirei Bioscience prediluted 60 min, CC1
WT1 6F-H2 Ventana-Roche 1:25 60 min, CC1
CEA COL-1 Nichirei Bioscience Prediluted 8 min, CC1
Claudin 4 3E2C1 Life Technologies 1:100 60 min, CC1
TTF-1 8G7G3/q Dako-Agilent 1:25 30 min, CC1
Napsin-A MRQ-60 Ventana-Roche prediluted 60 min, CC1
Epithelial Related Antigen MOC-31 Dako-Agilent 1:25 10 min, Protease
p63 DAK-p63 Dako-Agilent 1:25 60 min, CC1
CK5/6 D5/16 B4 Dako-Agilent 1:25 60 min, CC1
p40 BC28 Biocare Medical 1:100 60 min, CC1
Table 1. List of antibodies with their clone, commercial source, and reaction conditions. WT1: Wilm’s tumor 
1; CEA: carcinoembryonic antigen; TTF-1: thyroid transcription factor-1; CK: cytokeratin. Abbreviation: CC1, 
cell conditioning buffer 1 (Tris-based buffer, pH 8.5 from Ventana-Roche).
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control. It was present in 50 of 60 cases of adenocarcinoma (83.3%, Fig. 2B,D) and 50/56 cases of squamous cell 
carcinoma (89.3%, Fig. 2F,H). Among lung adenocarcinoma cases, 21 cases showed immunohistochemical score 
3+, 9 cases in score 2+, and 20 cases in score 1+. In lung squamous cell carcinoma, 21 cases showed score 3+, 10 
cases score 2+, and 19 cases score 1+.
In addition, we found no MUC4 expression in mesothelial layer of visceral pleura present in 39 lung cancer 
cases.
Antibody
Epithelioid Mesothelioma (65 cases) Lung Adenocarcinoma (60 cases)
Lung Squamous Cell Carcinoma 
(56 cases) Z-score!
Positive 
cases (%)
Immunohistochemical 
Score Positive 
cases (%)
Immunohistochemical 
Score Positive 
cases (%)
Immunohistochemical 
Score EM vs 
LAC
EM vs 
LSC0 1+ 2+ 3+ 0 1+ 2+ 3+ 0 1+ 2+ 3+
MUC4 0 (0) 65 0 0 0 50 (83.3) 10 20 9 21 50 (89.3) 6 19 10 21 8.0* 8.4*
Calretinin 64 (98.5) 1 5 2 57 17 (28.3) 43 11 6 0 28 (50) 28 13 10 5 9.1* 7.8*
D2–40 63 (96.9) 2 4 5 54 7 (11.7) 53 4 3 0 34 (60.7) 22 7 18 9 9.2* 6.7*
WT1 56 (86.2) 9 17 7 32 0 (0) 60 0 0 0 2 (3.6) 54 2 0 0 9.3* 9.1*
CEA 0 (0) 65 0 0 0 58 (96.7) 2 7 12 39 56 (100) 0 20 21 15 9.3* 9.5*
Claudin 4 0 (0) 65 0 0 0 57 (95) 3 2 10 45 55 (98.2) 1 3 34 18 9.5* 9.2*
TTF-1 0 (0) 65 0 0 0 54 (90) 6 2 6 46 5 (8.9) 51 5 0 0 8.7* 1.01
Napsin-A 0 (0) 65 0 0 0 48 (80) 12 9 3 36 2 (3.6) 54 2 0 0 7.7* 0.34
MOC-31 8 (12.3) 57 5 2 1 55 (91.7) 5 9 8 38 51 (91.1) 5 8 18 25 8.3* 7.8*
P63 15 (23.1) 50 11 3 1 32 (53.3) 28 16 10 6 56 (100) 0 1 2 53 3.2 9.0*
CK5/6 45 (69.2) 20 8 11 26 13 (21.7) 47 6 5 2 55 (98.2) 1 1 5 49 5.2* 4.6*
P40 3 (4.6) 62 3 0 0 6 (10) 54 5 1 0 55 (98.2) 1 0 3 52 0.52 9.1*
Table 2. Immunohistochemical Result of Epithelioid Mesothelioma, Lung Adenocarcinoma, and Squamous 
Cell Carcinoma. WT1: Wilm’s tumor 1; CEA: carcinoembryonic antigen; TTF-1: thyroid transcription factor-1; 
CK: cytokeratin. Immunohistochemical score 0: 0% positive cells or trace staining; 1+: 1–10% positive cells; 
2+: 11–50% positive cells; 3+: >51% positive cells! The Z-score is calculated by the MannWhitney ‘U’ test 
between immunohistochemical scores of epithelioid mesothelioma and lung cancer (adenocarcinoma or 
squamous cell carcinoma). EM: epithelioid mesothelioma; LAC: lung adenocarcinoma; LSqCC: lung squamous 
cell carcinoma *significant p-value (<0.0001).
Figure 1. Representative cases of epithelioid mesothelioma with papillo-tubular (A) and solid (C) growth 
showing no MUC4 expression (B,D). Note: normal bronchial epithelium as internal control showing MUC4 
expression. (A,C) H & E stain × 40 high power field; (B,D) MUC4 immunohistochemistry).
www.nature.com/scientificreports/
4SCIEnTIfIC RepoRts |  (2018) 8:134  | DOI:10.1038/s41598-017-18545-x
Calretinin, D2–40, WT1, and CK5/6. Calretinin expression was present in 64 cases (98.5%) of epithelioid 
mesothelioma with the immunohistochemical score of 3+ in 57. Calretinin expression was also present in 17 of 
60 (28.3%) cases of lung adenocarcinoma, and 28 of 56 (50%) cases of squamous cell carcinoma. The immuno-
histochemical of 3+ was not present in adenocarcinoma but was present in 5 cases of squamous cell carcinoma. 
D2–40 expression was present in 63 cases (96.9%) of epithelioid mesothelioma with the immunohistochemical 
score of 3+ in 54 cases. D2–40 expression was also present in 7 of 60 (11.7%) cases of lung adenocarcinoma 
and 34 of 56 (60.7%) cases of squamous cell carcinoma. The immunohistochemical score of 3+ was not present 
Figure 2. Representative cases of lung adenocarcinomas, papillary (2 A) or solid (2 C) growth and non-
keratinizing squamous cell carcinoma (E,G) showing MUC4 expression. (A,C,E,G): H & E stain × 40 high 
power field, (B,D,F,H): MUC4 immunohistochemistry).
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in adenocarcinoma but was present in 9 cases of squamous cell carcinoma. WT1 expression was present in 56 
(86.2%) epithelioid mesothelioma, with the immunohistochemical score of 3+ in 32 cases. WT expression was 
not present in any of the 60 adenocarcinomas but was present in 2 of 56 (3.6%) squamous cell carcinoma. CK5/6 
expression was present in 45 of 65 (69.2%) epithelioid mesothelioma, and 55 of 56 (98.2%) squamous cell car-
cinoma, and 13 of 60 (21.7%) adenocarcinoma. The majority of epithelioid mesothelioma and squamous cell 
carcinoma showed the immunohistochemical score of 3+ while in adenocarcinoma showed the immunohisto-
chemical score of 1+ to 3+.
CEA, Claudin 4, MOC-31. CEA and Claudin 4 expressions were not present in any of the epithelioid mes-
otheliomas. In contrast, CEA Expression was present in both 58 (96.7%) cases of lung adenocarcinoma and 56 
(100%) cases of squamous cell carcinoma. The majority of lung adenocarcinoma showed the immunohistochem-
ical score of 3+, and only one-fourth of CEA-positive lung squamous cell carcinoma showed the immunohisto-
chemical score of 3+.
Membranous Claudin 4 expression was present in 57 (95%) cases of adenocarcinoma with 39 cases showing 
the immunohistochemical score of 3+ and 55 (98.2%) cases of squamous cell carcinoma with 34 cases showing 
the immunohistochemical score of 2+.
MOC-31 expression was present in 55 (91.7%) and 51 (91.1%) cases of adenocarcinoma and squamous cell 
carcinoma. However, MOC-31 was also expressed in 8 (12.3%) epithelioid mesothelioma, of which, 5 cases 
showed the immunohistochemical score of 1+, 2 cases showed 2+, and 1 case showed 3+.
TTF-1, Napsin-A, p63, p40. Nuclear expression of TTF-1 and cytoplasmic expression of Napsin-A are 
the positive immunohistochemical markers of lung adenocarcinoma. TTF-1 and Napsin-A expression were not 
present in any of 65 (0%) cases of epithelioid mesothelioma and only 54 (90%) cases and 48 (80%) cases of lung 
adenocarcinoma. The immunohistochemical score of 3+ for TTF-1 and Napsin-A was observed in 46 and 36 
cases respectively. TTF-1 expression was also present in 5 (8.9%) cases, and Napsin-A expression in 2 (3.6%) cases 
of lung squamous cell carcinoma but with the immunohistochemical score of 1+.
Nuclear p63 expression and recently nuclear p40 expression are the positive immunohistochemical markers 
of lung squamous cell carcinoma. However, we found p63 and p40 expression in 15 (23%) and 3 (4.6%) cases of 
epithelioid mesothelioma although the immunohistochemical score was 1+. The p63 and p40 expression were 
present in 56 (100%), 55(98.2%) cases of squamous cell carcinoma and most of them with the immunohistochem-
ical score of 3+. However, 32 (53.3%) and 6 (10%) cases of adenocarcinoma also showed immunoreactivity for 
p63 and p40 respectively but with the immunohistochemical score of 1+.
Sensitivity, Specificity and accuracy rate of immunohistochemical markers. Table 3 shows the 
sensitivities, specificities, and accuracy rates of the immunohistochemical markers to differentiate epithelioid 
Mesothelioma from lung adenocarcinoma and squamous cell carcinoma. Among the negative mesothelioma 
markers, MUC4, CEA, Claudin 4, TTF-1, and Napsin-A showed 100% sensitivity, p40 showed 95.4%, P63 showed 
76.9%, and CK5/6 showed 69.2%. When the histological type was known as lung adenocarcinoma or squamous 
cell carcinoma, the specificity of TTF-1, Napsin-A and p40 were high, but with combined lung adenocarcinoma 
and squamous cell carcinoma, it remains around or less than 50%. Among the positive mesothelioma markers, 
WT1 showed the highest specificity of 98.6%, but sensitivity was limited to 86.2%. The sensitivities of calretinin 
and D2–40 were high with 98.5% and 96.9% respectively, but the specificities were low with 61.2%and 64.7% 
specificity. Among the negative mesothelial markers, CEA has the highest accuracy rate of 98.9% followed by 
Claudin 4 of 97.8%. The accuracy of MUC4 is 91.2% which is better than that of MOC-31.
Discussion
MUC4 is a transmembrane mucin expressed in normal epithelial cells including epithelial mucosa of the diges-
tive tract, ductal epithelium of salivary gland and lacrimal gland, larynx and trachea, lung, stomach, intestine, 
uterus, cervix, mammary gland, ovary, and kidney7. Many human malignancies like carcinomas of the pancreas8, 
ovary9, salivary gland10, lung11, stomach12, breast13 show MUC4 expression. MUC4 expression has been reported 
in the non-small cell lung cancer more in adenocarcinoma than do squamous cell carcinomas and large cell car-
cinomas14. MUC4 expression was also present significantly in solid adenocarcinoma of the lung15. In addition to 
poor prognosis correlated with MUC4 expression in the biliary tract, pancreas, ovary, and colorectal junction16, 
the MUC4 mRNA expression is related to the tumor histological type and its differentiation17. The tubular and 
papillary patterns of adenocarcinomas and the nests and in squamous pearls of squamous cell carcinomas show 
strong membranous and less cytoplasmic expression of MUC418. MUC4 plays a role in cell differentiation rather 
than cell proliferation of the normal goblet cells, the stratified squamous epithelial cells, and malignant epithelial 
tumor cells19. We previously reported the MUC4 expression in sarcomatoid carcinoma of the lung and its utility 
to differentiate from sarcomatoid mesothelioma20.
In this study, We found MUC4 expression in 50/60 (83.3%) cases of lung adenocarcinoma, 50/56 (89.3%) 
cases of squamous cell carcinoma, and none (0%) of epithelioid mesothelioma. Kwon et al.14  and Llinares et al.21  
previously reported the diagnostic value of MUC4 expression in distinguishing epithelioid mesothelioma and 
lung adenocarcinoma. They reported the diagnostic value of MUC4 immunostaining in distinguishing meso-
thelioma and lung adenocarcinoma. They raised the polyclonal antibody against a KLH conjugate of a synthetic 
peptide corresponding to the tandem repeat sequence of MUC4 for their study. They found that MUC4 was 
expressed in 0 of the 41 epithelioid mesotheliomas and 32 of the 35 (91%) lung adenocarcinoma. Our study uti-
lized the commercially available antibody and is the validation of the previous study. Other things different from 
this study is the inclusion of squamous cell carcinoma which also showed similar frequencies of positive cases like 
that of lung adenocarcinoma.
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Our data of MUC4 expression in adenocarcinoma and squamous cell carcinoma of lung is also similar to 
another study by Kwon et al. who studied MUC4 expression in lung adenocarcinoma and squamous cell carci-
noma of the lung but without mesothelioma.
In this study, we analyzed the utility of MUC4 to distinguish epithelioid mesothelioma from lung adeno-
carcinoma and squamous cell carcinoma. We have previously reported the MUC4 expression in sarcomatoid 
carcinoma of the lung and its utility to differentiate from sarcomatoid mesothelioma20. In our previous report, 
we emphasized the MUC4 expression in spindled cells of sarcomatoid carcinoma of lung. None of sarcomatoid 
mesothelioma had the expression of MUC4 expression. MUC4 was expressed in 72% of the sarcomatoid carci-
noma of lung.
Ordonez et al.22 reported that there is no absolute specific and sensitive marker of epithelioid mesothelioma, 
although the various immunohistochemical markers are currently available for the diagnosis of epithelioid mes-
otheliomas. He also added the location and histologic features of the tumor, the sex of the patient, and the clinical 
findings need to be considered when selecting the markers for accurate diagnosis of epithelioid mesothelioma 
from the various other carcinomas22.
Antibody Sensitivity, % Specificity, % Accuracy Rate, % p-value*
A. Differentiation of Epithelioid Mesothelioma from Lung Cancer including 
Adenocarcinoma and Squamous Cell Carcinoma
  MUC4(−) 100 86.2 91.2 <0.0001
  Calretinin(+) 98.5 61.2 74.6 <0.0001
  D2–40(+) 96.92 64.7 76.2 <0.0001
  WT1(+) 86.15 98.6 94.8 <0.0001
  CK5/6(+) 69.2 41.4 51.4 0.2
  CEA(−) 100 98.3 98.9 <0.0001
  Claudin 4(−) 100 96.6 97.8 <0.0001
  MOC31(−) 87.7 91.4 90 <0.0001
  TTF-1(−) 100 50.9 68.5 <0.0001
  NapsinA(−) 100 43.1 63.5 <0.0001
  P63(−) 76.9 75.2 76.2 <0.0001
  P40(−) 95.4 52.6 68 <0.0001
B. Differentiation of Epithelioid Mesothelioma from Lung Adenocarcinoma
  MUC4(−) 100 83.3 92 <0.0001
  Calretinin(+) 71.7 98.5 85.6 <0.0001
  D2–40(+) 88.3 96.9 92.8 <0.0001
  WT1(+) 100 86.2 92.8 <0.0001
  CK5/6(+) 69.2 78.3 73.6 <0.0001
  CEA(−) 100 96.7 98.4 <0.0001
  Claudin 4(−) 100 95 97.6 <0.0001
  MOC31(−) 87.7 91.7 89.6 <0.0001
  TTF-1(−) 100 90 95.2 0.02
  NapsinA(−) 100 80 90.4 0.21
  P63(−) 76.9 53.3 65.6 <0.0001
  P40(−) 95.4 10 54.4 <0.0001
C. Differentiation of Epithelioid Mesothelioma from Lung Squamous Cell 
Carcinoma
  MUC4(−) 100 89.3 95 <0.0001
  Calretinin(+) 98.5 50 76 <0.0001
  D2–40(+) 97 39.3 70.2 <0.0001
  WT1(+) 86.2 96.4 91 <0.0001
  CK5/6(+) 69.2 1.8 38 <0.0001
  CEA(−) 100 100 100 <0.0001
  Claudin 4(−) 100 98.2 99.2 <0.0001
  MOC31(−) 87.7 91.1 89.3 <0.0001
  TTF-1(−) 100 8.9 57.9 <0.0001
  NapsinA(−) 100 3.6 55.4 <0.0001
  P63(−) 76.9 100 88.5 0.008
  P40(−) 95.4 98.2 96.7 0.31
Table 3. Sensitivity, Specificity, and Accuracy Rate of Immunohistochemical Markers. WT1: Wilm’s tumor 1; 
CEA: carcinoembryonic antigen; TTF-1: thyroid transcription factor-1; CK: cytokeratin. *p-value is calculated 
by Fisher’s exact test.
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The sensitivity and specificity of MUC4 to differentiate epithelioid mesothelioma from lung adenocarcinoma 
were 100% and 83.3% respectively with the accuracy rate of 92% and those of MUC4 to differentiate epithe-
lioid mesothelioma from lung squamous cell carcinoma 100% and 89.3% respectively with the accuracy rate 
of 95%. We found CEA is the best marker with the sensitivity of 100%, specificity of 98.3%, and accuracy rate 
of 98.9% followed by Claudin 4 which had the sensitivity of 100%, specificity of 96.6%, and accuracy rate of 
97.8%. MUC4 expression showed a similar sensitivity of 100%, but the lower specificity of 86.2% and accuracy 
rate of 91.2%. However, it showed better sensitivity, specificity and accuracy rate than that of MOC-31. Also, we 
found positive immunoreactivity for MUC4 in some cases of adenocarcinoma and squamous cell carcinoma with 
no CEA and/or Claudin 4 expression. Two cases of CEA-negative adenocarcinoma, one of which was negative 
for Claudin 4 too, showed MUC4 expression (immunohistochemical score of 2+ or 3+). Moreover, 3 cases of 
Claudin 4-negative adenocarcinoma, two of which were negative for CEA too, showed MUC4 expression (immu-
nohistochemical score of 1+ or 2+). There was one adenocarcinoma case which was negative for both CEA 
and Claudin-4 but positive MUC4 expression. So, MUC4 has the potential for the use as an additional negative 
marker of epithelioid mesothelioma for differentiation from lung cancer including adenocarcinoma or squamous 
cell carcinoma.
International Mesothelioma Interest Group Guideline for pathologic diagnosis of malignant mesothelioma 
has recommended various immunohistochemical negative markers, CEA, MOC-31, TTF-1, Napsin-A to dif-
ferentiate it from adenocarcinoma and p40, p63, MOC-31 to differentiate it from squamous cell carcinoma4. 
Ordonez et al. later added Claudin 4 as one of the best broad-spectrum carcinoma markers to discriminate epi-
thelioid mesotheliomas from both lung adenocarcinomas and squamous cell carcinomas23. In our previous publi-
cation too, we found CEA and Claudin 4 were the best positive carcinoma markers for discriminating epithelioid 
mesotheliomas from squamous cell carcinomas24. Although p63 is the marker of squamous cell carcinoma, it was 
at least focally positive in many of adenocarcinoma (32/60, 53.3%) and epithelioid mesothelioma (15/65, 23.1%) 
in the present study. So, limiting the value of the p63 expression for differentiation of epithelioid mesothelioma 
from squamous cell carcinoma.
In conclusion, MUC4 can be added as additional positive marker of non-small cell carcinoma (both lung 
adenocarcinoma and squamous cell carcinoma) and negative immunohistochemical marker to differentiate epi-
thelioid mesothelioma from lung adenocarcinoma and squamous cell carcinoma. This study includes the limited 
cases (65 epithelioid mesothelioma and 116 cases of lung adenocarcinoma and needs follow up study consisting 
of large numbers of cases.
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